A phase I study of the WT2725 dosing emulsion in patients with advanced malignancies

A phase I study of the WT2725 dosing emulsion in patients with advanced malignancies

Abstract WT2725 is a Wilms’ tumor gene 1 (WT1)-derived-oligopeptide vaccine designed to induce WT1-specific cytotoxic T-lymphocytes against WT1+ tumors in human leukocyte antigen (HLA)-A*0201+ and/or HLA-A*0206+ patients. Here, we report the results of a phase I study of WT2725. In this phase I, ope...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Siqing Fu, David E. Piccioni, Hongtao Liu, Rimas V. Lukas, Santosh Kesari, Dawit Aregawi, David S. Hong, Kenichiro Yamaguchi, Kate Whicher, Yi Zhang, Yu-Luan Chen, Nagaraju Poola, John Eddy, David Blum
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/60746137df784b578782dc3342f39baf
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/60746137df784b578782dc3342f39baf

Ejemplares similares